Oncology Institute, Inc. TOI
Institutional shares held
27.9 Million
0
calls
0
puts
Total value of holdings
$115M
$0
calls
$0
puts
Market Cap
$302M
73,495,504
Shares Out.
Institutional ownership
38.0%
# of Institutions
78
We take great care to ensure that the data presented and summarized in this overview for Oncology Institute, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TOI
View all-
Vanguard Group Inc Valley Forge, PA4.28MShares$17.6 Million0.0% of portfolio
-
Tiff Advisory Services Inc3.63MShares$14.9 Million1.76% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.36MShares$13.8 Million0.16% of portfolio
-
Balyasny Asset Management LLC Chicago, IL2.52MShares$10.4 Million0.01% of portfolio
-
Kent Lake Capital LLC Mill Valley, CA1.75MShares$7.19 Million0.37% of portfolio
-
Marshall Wace, LLP London, X01.48MShares$6.07 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.28MShares$5.26 Million0.0% of portfolio
-
Wexford Capital LP Greenwich, CT1.12MShares$4.6 Million0.74% of portfolio
-
Center Book Partners LP Greenwich, CT716KShares$2.94 Million0.09% of portfolio
-
State Street Corp Boston, MA646KShares$2.66 Million0.0% of portfolio
Latest Institutional Activity in TOI
Top Purchases
Top Sells
About TOI
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Insider Transactions at TOI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 24
2025
|
Richard A Barasch Director |
SELL
Other acquisition or disposition
|
Indirect |
287,756
-9.84%
|
-
|
|
Jul 22
2025
|
Kristin England Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
98,037
+50.0%
|
-
|
|
Jun 18
2025
|
Richard A Barasch Director |
BUY
Conversion of derivative security
|
Indirect |
620,400
+19.53%
|
-
|
|
Jun 17
2025
|
Richard A Barasch Director |
SELL
Payment of exercise price or tax liability
|
Indirect |
311,128
-9.62%
|
$622,256
$2.62 P/Share
|
|
Jun 17
2025
|
Richard A Barasch Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
679,224
+17.35%
|
$679,224
$1.2 P/Share
|
|
Jun 17
2025
|
Richard A Barasch Director |
BUY
Conversion of derivative security
|
Direct |
159,500
+7.61%
|
-
|
|
Jun 05
2025
|
M33 Growth I L.P. Director |
SELL
Open market or private sale
|
Indirect |
76,324
-5.66%
|
$228,972
$3.05 P/Share
|
|
Jun 05
2025
|
M33 Growth I L.P. Director |
SELL
Open market or private sale
|
Direct |
673,676
-4.61%
|
$2,021,028
$3.05 P/Share
|
|
Jun 03
2025
|
Brad Hively Director |
SELL
Open market or private sale
|
Direct |
1,976,137
-43.82%
|
$3,952,274
$2.87 P/Share
|
|
Jun 03
2025
|
Brad Hively Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,867,605
+18.43%
|
$1,867,605
$1.01 P/Share
|
|
May 21
2025
|
Jeffrey Langsam Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
57,380
+50.0%
|
-
|
|
May 21
2025
|
Daniel Virnich Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,388
-1.13%
|
$40,776
$2.67 P/Share
|
|
May 21
2025
|
Yale Podnos Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,801
-0.76%
|
$3,602
$2.67 P/Share
|
|
May 21
2025
|
Robert Ross Carter Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,601
-0.68%
|
$3,202
$2.67 P/Share
|
|
May 21
2025
|
Jeremy Castle Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,636
-2.23%
|
$11,272
$2.67 P/Share
|
|
May 20
2025
|
M33 Growth I L.P. Director |
SELL
Open market or private sale
|
Indirect |
203,532
-13.11%
|
$407,064
$2.71 P/Share
|
|
May 20
2025
|
M33 Growth I L.P. Director |
SELL
Open market or private sale
|
Direct |
1,796,468
-10.94%
|
$3,592,936
$2.71 P/Share
|
|
Mar 31
2025
|
Yale Podnos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
157,088
+39.95%
|
-
|
|
Mar 31
2025
|
Robert Ross Carter Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
197,368
+45.46%
|
-
|
|
Mar 31
2025
|
Jeremy Castle Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
162,281
+39.11%
|
-
|
Last 12 Months Summary
Buy / Acquisition
10M
Shares
From
25
Insiders
| Grant, award, or other acquisition | 4.85M shares |
|---|---|
| Conversion of derivative security | 780K shares |
| Open market or private purchase | 1.84M shares |
| Exercise of in-the-money or at-the-money derivatives securities | 679K shares |
| Exercise of conversion of derivative security | 1.87M shares |
Sell / Disposition
22.3M
Shares
From
13
Insiders
| Other acquisition or disposition | 17.2M shares |
|---|---|
| Payment of exercise price or tax liability | 311K shares |
| Sale (or disposition) back to the issuer | 58.2K shares |
| Open market or private sale | 4.73M shares |